Imatinib in Adult Patients With Metastatic Ocular Melanoma
The scope of the trial is to determinate the anti-tumoral activity of imatinib in metastatic ocular melanoma patients.
Melanoma
DRUG: Imatinib
Progression-free rate at 3 months
Progression-free rate at 6 and 12 months|Response rate according to RECIST criteria|Toxicity|Global survival,Progression-free survival|Predictive genomic factors of response
Further study details as provided by Centre Oscar Lambret